Aegis Capital Starts Navidea Biopharmaceuticals (NAVB) at Hold
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Burrill Starts Navidea Biopharmaceuticals (NAVB) at Market Outperform
January 22, 2013 7:21 AM ESTBurrill initiates coverage on Navidea Biopharmaceuticals (NYSE: NAVB) with a Market Outperform. PT $5.00.
The firm comments, "Navidea is currently seeking regulatory approval of Lymphoseek, a precision radiopharmaceutical agent used for intraoperative lymphatic mapping, and in our opinion, addresses a $300 MM worldwide market. In... More